ArticleNature communications2020
Timing the initiation of multiple myeloma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 158 citations in OpenAlex.
- Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.Nature medicine · 2026Article
- Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.Cancer research · 2026Article
- Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.Blood cancer discovery · 2026Article
- Fluctuating environment causes neoplastic transition and epithelial-mesenchymal plasticity in human cells.Research square · 2026Article
- Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.Blood cancer journal · 2026Article
- Review
- Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study.Research square · 2026Article
- Machine Learning Model Predicts Monoclonal Gammopathy Using Routine Laboratory Values.JCO clinical cancer informatics · 2026Article
- Review
- Article
- Global epidemiology and burden of multiple myeloma from 1990 to 2021 with projections to 2045 based on the global burden of disease study 2021.Discover oncology · 2026Article
- Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Genomics Define Malignant Transformation in Myeloma Precursor Conditions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Mutational signatures in hematological malignancies.Einstein (Sao Paulo, Brazil) · 2026Review
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.bioRxiv : the preprint server for biology · 2025Article
- Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma.Cells · 2025Review
- Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.Blood cancer discovery · 2025Article
- Cancer Cell Dormancy in the Bone Microenvironment.Current osteoporosis reports · 2025Review
- Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 12 institutions in 6 countries.
Even H Rustad *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-9320-4963
Venkata Yellapantula *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel LeongamornlertThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Niccolò BolliDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Guy LedergorDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0443-6066
Ferran NadeuPatologia Molecular de Neoplàsies Limfoides, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2910-9440
Nicos AngelopoulosThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.ORCID http://orcid.org/0000-0002-7507-9177
Kevin J DawsonThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Thomas J MitchellThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.ORCID http://orcid.org/0000-0003-0761-9503
Robert J OsborneThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Bachisio ZicchedduDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Cristiana CarnitiDepartment of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Vittorio MontefuscoDepartment of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paolo CorradiniDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0002-9186-1353
Kenneth C AndersonJerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Philippe MoreauCRCINA, SIRIC ILIAD, University Hospital of Nantes, Nantes, France.
Elli PapaemmanuilComputational Oncology Service, Department of Epidemiology & Biostatistics, Center for Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, University of California, La Jolla, San Diego, CA, USA.ORCID http://orcid.org/0000-0003-3596-4515
Xose S PuenteUnitat Hematopatologia, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9525-1483
Elias CampoPatologia Molecular de Neoplàsies Limfoides, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9850-9793
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Herve Avet-LoiseauIUC-Oncopole, and CRCT INSERM U1037, 31100, Toulouse, France.
Ola LandgrenMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6485-4839
Nikhil MunshiJerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Peter J CampbellThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.ORCID http://orcid.org/0000-0002-3921-0510
Francesco MauraMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mauraf@mskcc.org.ORCID http://orcid.org/0000-0002-5017-1620
Wellcome Sanger Institute · GBMemorial Sloan Kettering Cancer Center · USUniversity of Milan · ITCentro de Investigación Biomédica en Red de Cáncer · ESFondazione IRCCS Istituto Nazionale dei Tumori · ITHarvard University · USInserm · FRNantes Université · FRUniversidad de Oviedo · ESUniversität Ulm · DEUniversity of California San Diego · USUniversity of California, San Francisco · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTrageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0MTargeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI RICHARD YOUNG · 2011 to 2026
$32.5MMOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSEI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MUNSHI, NIKHIL C. · 2013 to 2025
–BLRD VA I01 BX001584Cancer Research UK 27176NCI NIH HHS P01 CA155258NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA100707
Abstract
The evolution and progression of multiple myeloma and its precursors over time is poorly understood. Here, we investigate the landscape and timing of mutational processes shaping multiple myeloma evolution in a large cohort of 89 whole genomes and 973 exomes. We identify eight processes, including a mutational signature caused by exposure to melphalan. Reconstructing the chronological activity of each mutational signature, we estimate that the initial transformation of a germinal center B-cell usually occurred during the first 2
Indexed as
Gene Expression Regulation, NeoplasticAICDA (Activation-Induced Cytidine Deaminase)APOBEC-1 DeaminaseCytidine DeaminaseDNA Mutational AnalysisEarly Detection of CancerExomeGeneticsGerminal CenterHumansLinear ModelsMinor Histocompatibility AntigensMultiple MyelomaMutationProteinsRNA EditingAICDA (Activation-Induced Cytidine Deaminase)APOBEC-1 DeaminaseAPOBEC1 protein, humanAPOBEC3A protein, humanAPOBEC3B protein, humanCytidine DeaminaseMinor Histocompatibility AntigensProteinsRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.